Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 10/20 | 0.72 |
| ▸ | CA12 | O43570 | 9/20 | 0.72 |
| ▸ | CA1 | P00915 | 9/20 | 0.72 |
| ▸ | CA9 | Q16790 | 9/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12305496 | 0.89 | POLB (0.80) | POLBCYP1A2CA2CA12CA1 | |
| SCHEMBL6673848 | 0.82 | KDM4E (1.00) | POLBCYP1A2CA2CA12CA1 | |
| SCHEMBL27483940 | 0.81 | POLB (0.68) | POLBCYP1A2CA2CA12CA1 | |
| SCHEMBL21751022 | 0.81 | KDM4E (0.79) | POLBCYP1A2CA2CA12CA1 | |
| SCHEMBL671546 | 0.80 | CA2 (1.00) | CYP1A2CA2CA12CA1CA9 | |
| SCHEMBL3406989 | 0.80 | CA2 (0.70) | POLBCYP1A2CA2CA12CA1 | |
| SCHEMBL672763 | 0.80 | CA12 (1.00) | POLBCYP1A2CA2CA12CA1 | |
| SCHEMBL28499329 | 0.80 | KMT2A (1.00) | CA2CA12CA1CA9MAPT | |
| SCHEMBL1276481 | 0.80 | KDM4E (0.82) | POLBCYP1A2KDM4EMAPTRAB9A | |
| SCHEMBL30393282 | 0.80 | KDM4E (0.82) | POLBCYP1A2KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011014299-A2 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20100120754-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | OETTGEN PETER | 2010-05-13 | — | — | US | disclosed |
| WO-2008066672-A2 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120754-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | TEAD1, CREBBP, TEAD2 | POLB 798/4885CYP1A2 3854/4885CA2 4355/4885 |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | CREBBP, TEAD1, SREBF1 | POLB 752/4885CYP1A2 2189/4885CA2 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.